Clinical trials: Head or Neck Cancer
HPV 16+ Recurrent or Metastatic Cancer, HNSCC
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.
- Conditions
- HPV 16+ Recurrent or Metastatic Cancer, HNSCC, Cervical Cancer
- Trial name
- NCT07081984
- Testing
- therapeutic tumor vaccine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
This phase II trial investigates the effect of NBTXR3, radiation therapy, and pembrolizumab in treating patients with head and neck squamous cancer that has come back (recurrent) or has spread to other places in the body…
- Trial name
- NCT04862455
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Hypofractionated Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03889899
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Esophageal Squamous Cell Carcinoma (ESCC)
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or…
- Trial name
- NCT07481058
- Testing
- KC1036, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of Esophagus
Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.
Interest of continuing systemic chemotherapy or not , after a short initial treatment (6 weeks) in patients who are in response or stable disease("Discontinuation design ")of patients with metastatic oesophageal cancer of…
- Trial name
- E-DIS (NCT01248299)
- Testing
- FU-CDDP, LV5FU2-CDDP, FOLFOX
- Where
- 17 sites in France
- Volunteers
- 105 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Neoplasms, Squamous Cell Carcinoma
Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer
Metformin plus paclitaxel for recurrent or metastatic head and neck cancer: a randomized phase II trial
- Trial name
- METTAX (NCT01333852)
- Testing
- metformin up to 2500mg/d, paclitaxel 175mg/m² q21d
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Lucas Vieira dos Santos
Neack and Head Cancer, Supervised Execise Program
The SEHNeCa Supervised Exercise Project
Objectives: To evaluate the effectiveness and efficiency of an innovative supervised exercise program for patients with head and neck cancer (SEHNeCa) to ameliorate loss of lean body mass, functional capacity and quality of life…
- Trial name
- SEHNeCa (NCT04658706)
- Testing
- A supervised exercise program, exercise prescription
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Basque Health Service
Head and Neck Cancer
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine hydrochloride, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00997906
- Testing
- carboplatin,, cisplatin, gemcitabine hydrochloride
- Where
- Singapore
- Volunteers
- 172 people
- Sponsor
- National Cancer Centre, Singapore
Squamous Cell Carcinoma
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck
This study will test the safety and effects of the experimental drug PS-341 plus radiation therapy in patients with head and neck cancer. PS-341 can slow or halt the growth of cancer cells grown in culture or in mice.
- Trial name
- NCT00011778
- Testing
- bortezomib, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Head and Neck
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00725764
- Testing
- GSK1363089 (foretinib)
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Oropharyngeal Cancer
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+…
- Trial name
- NCT07290621
- Testing
- Toripalimab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Several prospective randomized trials have demonstrated that concurrent chemoradiotherapy was superior to radiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02434614
- Testing
- Docetaxel,Cisplatin,Fluorouracil, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 6 sites in China
- Volunteers
- 440 people
- Sponsor
- Wei Jiang
Non-Melanoma Skin Cancer
Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project
Mohs surgery excises non-melanoma skin cancer tumors of the head and neck while preserving maximum healthy tissue, an advantageous characteristic when dealing with the cosmetic and functional cervifacial region.
- Trial name
- NCT01452984
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Esophageal Squamous Cell Carcinoma, Esophageal Cancer
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in patients with Stage IIB or III squamous…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer
- Trial name
- NCT02465736
- Testing
- Docetaxel, Cisplatin, Radiation
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Sun Yat-sen University
Cervical Cancer, Anal Cancer
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers.
- Conditions
- Cervical Cancer, Anal Cancer, Head and Neck Cancers
- Trial name
- NCT05122221
- Testing
- Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Oral Squamous Cell Carcinoma
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of TC Regimenwith or without nimotuzumab in recurrent metastatic oral squamous cell carcinoma.
- Trial name
- NCT04367909
- Testing
- Nimotuzumab, Docetaxel, Carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Xin-Hua Xu
Esophagus Cancer, Chemoradiation
Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
The aim of this observational study is to retrospectively collect survival data for 3000 primary esophageal cancer patients from multicenter between January 2000 to present.
- Conditions
- Esophagus Cancer, Chemoradiation, Chemotherapy Effect, Radiotherapy Side Effect
- Trial name
- NCT03298204
- Where
- China
- Volunteers
- 2,762 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
This phase II trial is studying how well decitabine works in treating patients with metastatic papillary thyroid cancer or follicular thyroid cancer that has stopped responding to radioactive iodine.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00085293
- Testing
- Decitabine, Iodine I 131, Recombinant thyrotropin alfa
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.